4 terminated, 3 completed, 1 recruiting. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 4, Completed 3, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow siponimod: new trials by email Literature Review of siponimod trials Research Report on siponimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repurposing Siponimod for Alzheimer's Disease Siponimod, Placebo - Alzheimer Disease, Mild Alzheimer Disease | Phase 2 | Recruiting | St. Joseph's Hospital and Medical Center, Phoenix | 105 | 2025-08-26 | 2026-03-04 |
| Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis Mayzent, Ocrevus - Secondary-progressive Multiple Sclerosis | Phase 2 / Phase 3 | Terminated | State University of New York at Buffalo | 8 | 2021-11-13 | 2025-05-13 |
| Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). BAF312 solution, Matching Placebo for BAF312 solution, BAF312 tablet - Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH) | Phase 2 | Completed | Novartis Pharmaceuticals | 32 | 2017-12-24 | 2022-08-12 |
| Safety and Efficacy of BAF312 in Dermatomyositis BAF312, Placebo - Active Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 17 | 2013-08-25 | 2021-01-05 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis Placebo, BAF312 - Polymyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 14 | 2013-04-24 | 2021-01-05 |
| Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis BAF312 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2010-08-30 | 2018-03-27 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis BAF312, Placebo - Polymyositis, Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2010-06-15 | 2019-04-25 |
| Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis BAF312, Placebo - Relapsing-remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 297 | 2009-03-30 | 2020-01-13 |
Dermatomyositis (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Myositis (2) · Myositis, Inclusion Body (2) · Polymyositis (2) · Alzheimer Disease (1) · Cerebral Hemorrhage (1) · Cognitive Dysfunction (1) · Deglutition Disorders (1) · Demyelinating Diseases (1) · Diffuse Cerebral Sclerosis of Schilder (1) · Exanthema (1) · Hemorrhagic Stroke (1) · Multiple Sclerosis, Chronic Progressive (1)
Novartis Pharmaceuticals (6) · St. Joseph's Hospital and Medical Center, Phoenix (1) · State University of New York at Buffalo (1)
United States (8) · Hungary (4) · Canada (3) · Czechia (3) · Poland (3) · Finland (2) · Germany (2) · Italy (2) · Norway (2) · Russia (2) · Spain (2) · Switzerland (2) · Turkey (Türkiye) (2) · Japan (1) · Sweden (1)
Boris Decourt, PhD (1) · Kevin N. Sheth, MD (1) · Marwan N Sabbagh, MD (1)
PMID 23764350, PMID 26083135, PMID 27380540
2008 (2), 2009 (1), R01AG073212 (1)